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Osteogenesis, vascularization and osseointegration of a bioactive 
multiphase macroporous scaffold in the treatment of large bone 
defects 
Linyang Chu,a Guoqiang Jiangb, Xi-Le Hu,c* Tony D. James,d Xiao-Peng He,c Yaping Lib* and Tingting 
Tanga* 
Bone grafting remains the method of choice for the majority of surgeons in the treatment of large bone defects, since it fills 
spaces and provides support to enhance biological bone repair. Recently, we reported our research on a bioactive 
multiphase macroporous scaffold with interconnected porous structure, nano-crystal surface microstructure that can 
release bioactive ions. Moreover, we demonstrated the excellent in vitro biological activity of the scaffold. With this study, 
we set out to evaluate the in vivo, osteogenesis and vascularization of the scaffold in the treatment of large bone defects 
(10-mm radial bone defect in rabbits). In comparison with the control group, X-ray and Micro-CT results at the 4th and 8th 
week post-surgery the bioactive scaffold displayed an enhanced level of new bone and vessel formation. Histological results 
at the same weeks indicated improved bone formation, osseointegration and new vessel ingrowth inside the bioactive 
scaffold. These findings establish a good foundation for the potential clinical validation of the bioactive macroporous 
biomaterial scaffold for use as a bone substitute or in tissue engineering.
1.Introduction 
Autologous bones are the gold-standard of graft materials, 
providing many active factors for bone ingrowth. However, 
problems still exist, such as resorption, fatigue failure, fracture, 
secondary infection and the limited supply of autologous 
bones.1-3 Therefore, research into the development of bone 
substitute materials for potential clinical validation is an 
important focus of medical research.4 Biomaterial scaffolds 
have been developed extensively for bone restoration.5-7 
However, an ideal bone substitute or tissue engineering scaffold 
should be osteoinductive, osteoconductive, biocompatible and 
possess an interconnected structure with high porosity.8 
Hydroxyapatite (HA, Ca5(PO4)3(OH)) has been considered to be 
a good substitute for bone tissue regeneration due to its 
recognized compatibility and osteoconductivity. However, its 
brittleness, low mechanical stability and high stability in the 
human body limit its application in bone tissue engineering.8-9 
Additionally, previous studies have suggested that single-phase 
materials could not perfectly meet the needs of tissue 
engineering scaffolds.10-11  
 
Scheme 1. A segmental radial bone defect model used to evaluate the in vivo 
osteogenesis, vascularization and osseointegration of the bioactive multiphase 
macroporous scaffold with interconnected porous, nano-crystal surface microstructure 
that can release bioactive ions. 
To overcome these problems, multiphase materials modified 
and functionalized by various chemical processes in order to 
render them bioactive are urgently required. It has been 
reported that the osteogenic capacity and mechanical 
properties of biomaterials could be improved by chemical 
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modification, i.e., by formation of functional sulfo groups or 
chemical mechanical polishing.12,13 Chemical modification for 
bone substitutes or scaffolds could lead to diversified bioactivity 
as well as new opportunities for bone tissue engineering. 
In our previous investigation, we used hydrothermal 
calcination to develop a bioactive multiphase macroporous 
scaffolds with interconnected porous, nano-crystal surface 
microstructures capable of releasing bioactive ions.14 We 
demonstrated that these bioactive scaffolds with good 
biocompatibility possessed excellent osteogenesis and 
vascularization capacity in vitro. Moreover, we determined that 
the scaffold exhibited excellent efficacy for tissue integration in 
a dorsum subcutaneous implantation model. These results 
unambiguously provided a basis for subsequent in vivo 
investigations. Therefore, with the present study we sought to 
examine the potential of the scaffold for bone regeneration 
using a standard segmental radial bone defect model in rabbits. 
Techniques including radiographs, Micro-CT and histological 
analyses were used. Since it is known that bioactive material 
scaffolds can promote neovascularization in order to further 
facilitate the osteogenic potential,15 the present study also 
adopted angiography to test vessel formation within the 
scaffold and local blood perfusion. We envision that the 
bioactive macroporous scaffold could be an ideal biomaterial 
for use as a bone substitute or in tissue engineering. 
 
2. Experimental Section 
2.1 Materials 
The bioactive macroporous scaffold was fabricated according to 
our previous method.14 In brief, the calcined and cleaned bovine 
cancellous bone (its main composition is HA) and a solution of 
Mg2+, PO43- and SO42- were mixed and the system was then 
sujected to hydrothermal reaction for 36 h at 75 °C. The scaffold 
was then placed in a temperature-controlled calcination 
furnace at 1050 °C for 6 h to obtain the desired HA/Ca/Mg 
scaffold (additional Ca(3-n)Mgn(PO4)2 and CaSO4 was produced). 
The HA/Ca/Mg scaffold perserved the natural interconnected 
porous structure, connectivity and pore size. Nano-crystal, 
whisker-like microstructures were formed on the HA/Ca/Mg 
scaffold surface. A pure macroporous scaffold (HA) without 
hydrothermal reaction (TCP) widely used in clinical practice was 
used as control.16,17 
 
2.2 Characterization of scaffolds used in vivo 
All scaffolds used in animal model were trimmed into cylinders 
with a diameter of 4 mm and length of 10 mm in order to fit into 
the bone defects. The scaffolds were dried, coated by gold 
sputtering, and examined using a scanning electron microscope 
(SEM, Japan) at an electron acceleration voltage of 1.5 kV in 
secondary electron detection mode to visualize the surface 
microstructure. 
 
2.3 Establishment of segmental radial bone defects in rabbits 
A segmental radial bone defect model in adult male rabbits was 
used in the present study.18-21 All procedures were approved 
and performed in accordance with the guidelines of the Animal 
Ethics Committee of Shanghai Ninth People’s Hospital. In brief, 
male rabbits of 5 months old weighing 3.5-4 kg were 
anaesthetized by ear intravenous injection of 1.5% 
pentobarbital (1 mL kg-1). Then, bilateral forelimbs of rabbits 
were shaved, prepped with 70% ethanol, and then the radius 
was exposed through a longitudinal incision of the skin. A 
segment of radial bone with a length of 10 mm, which was 
regarded as a sub-critical sized defect, was surgically removed. 
Scaffolds were press fit into the radial defects and the wound 
was carefully closed with layers of sutures. Pressure bandages 
were used to protect the wound for three post-surgery days. 
 
2.4 X-ray evaluation of newly formed bone 
High-resolution radiographs of the operated radius were taken 
at post-operative weeks of 0, 4 and 8, using an X-ray machine 
(Faxitron X-ray Corporation, USA) with an exposure time of 3 s.22 
 
2.5 Micro-CT evaluation of newly formed bone 
At post-operative weeks 4 and 8, newly formed bones were 
characerized using a high-resolution Micro-CT (Scanco Medical, 
μCT-80, Switzerland) at an isometric resolution of 10 μm 
according to published protocols.19 Briefly, the bony 
compartment was segmented from the marrow and soft tissue 
for subsequent analyses using a global threshold procedure. A 
threshold equal to or above 150 represented bony tissue; a 
threshold below 150 represented bone marrow, soft tissue and 
implanted composite scaffolds.23 The new bone formed within 
the bone defect region was acquired for quantification of tissue 
volume (TV), bone volume (BV) and bone mineral density 
(BMD). 
 
2.6 Micro-CT evaluation of vascularization 
Microfil perfusion was conducted in the forelimbs of rabbits. 
Briefly, under deep general anaesthesia, the bilateral arteria 
axillaries and vena axillaries of the animals were separated and 
inserted with needles that were linked to a pump apparatus 
with a flow speed at 20 mL min-1 for perfusion. The vasculature 
was adequately flushed with pre-warmed heparinized saline 
and injected with a solution of Microfil (Microfil, Flow Tech, Inc., 
USA) prepared in a volume ratio of 4/5 of Microfil/diluent with 
5% curing agent based on the manufacturer’s protocol.18 Then, 
bilateral forelimbs were harvested, fixed with 4% neutral-
buffered formaldehyde for 48 h and decalcified with 9% formic 
acid for 4 weeks. The vascularization of radial defects was 
reconstructed using Micro-CT at an isometric resolution of 10 
μm. Three-dimensional reconstruction of the newly formed 
vessels and their volume were analyzed by the software 
provided by manufacturer.24 The evaluation was obtained using 
four samples randomly selected from each group. 
 
2.7 Decalcified histological evaluation 
The samples were fixed in 10% neutral buffered formaldehyde 
for 3 days, decalcified for 1 week using Rapidly Decalcifier (DeCa 
DX-1000; Pro-Cure Medical Technology Co Ltd, Hong Kong) and 
then embedded in paraffin. Lastly sections of specimens at a 
thickness of 5 μm were prepared along the long axis and coronal 
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plane of the radial defect region using a microtome (CUT 6062; 
SLEE Medical, Germany). 
Sections with H&E, Giemsa, Safranin O-fast green, Sirius red 
and Masson’s trichrome staining were digitalized into a 
microscopic system for descriptive histology of the appearance 
of newly formed bone and quantitative histomorphometry.18, 25-
27 The area of newly formed bone in total implants area within 
the bone defects were quantified separately using an Image-pro 
Plus software system (Media Cybernetics, USA).19 Four serial 
sections from each sample were used to provide an average for 
statistical analysis. Meanwhile, CD31 immunohistochemistry 
was used to assess vessel ingrowth. Sections were dewaxed in 
alcohol, rehydrated and immersed into 3% hydrogen peroxide 
to block endogenous peroxidases and then rinsed in PBS. The 
slides were immersed into 0.1% Triton-X100 to allow 
penetration of the membrane for 15 min. Antigen retrieval was 
carried out in a 10 mM warm citrate buffer for 15 min. Specific 
sites were saturated with normal goat serum for 40 min at 37 
°C. The monoclonal anti-CD31 antibody (ab76533, Abcam) was 
used. The sections were incubated with biotinylated rabbit anti-
rabbit immunoglobulins, washed in TBS for 5 min and incubated 
for 30 min with streptavidin–peroxidase (1 : 50, DAKO). The 
nuclei were counter stained with H&E for 2–3 s, washed in 
distilled water and finally covered with Aqua Tex (Merck, 
Germany). 
 
2.8 Undecalcified histological evaluation 
Two fluorescence dyes, calcein and alizarin red were used to 
test the bone dynamic remodeling within segmental bone 
defect using established protocols.28 In brief, calcein (10 mg kg-
1) and alizarin red (30 mg kg-1) were injected subcutaneously 
and sequentially into the rabbits of weeks 4 and 8 at day 14 and 
day 7 before euthanasia. The samples of the radial bone defects 
were fixed in 10% neutral buffered formaldehyde for 2 days. 
Then, the samples were placed into an embedded device 
containing methylmethacrylate (MMA, Mecck-Schuchardt, 
Germany) monomer and stored at 4 °C. After 1 week, the MMA 
monomer was discarded. Colloidal MMA was added and stored 
at room temperature until solidified. The embedded fragments 
containing the tissue specimens were collected and cut into 150 
μm sections with a microtome (SP1600, Leica, Germany). Then, 
the sections were adhered to organic glass slides and 
compressed for 24 h. The thickness of the section was polished 
to 50 μm using P600, P800, and P1200 abrasive paper followed 
by burnishing with flannelette and abradum to 20–30 μm. 
The fluorescence of the new bones formed was visualized by 
confocal laser scanning microscopy (CLSM, Leica, Germany). 
Then at least four sections of each implant were stained with 
picric acid/fuchsine.28 Briefly, the histological sections were 
soaked in 1% formic acid for 3 min, rinsed with running water 
for 5 min, and dried. Then the histological sections were soaked 
in 20% methanol for 2 h, and the picric acid/fuchsin staining was 
performed. The histological sections were preheated at 60 °C, 
stained with Stevenol blue for 5-15 min, rinsed with distilled 
water and dried, stained with the VG staining solution for 3-8 
min, cleaned with pure ethanol, and dried. An optical 
microscope (Leica Microsystems AG, Germany) was used for 
histological evaluation. Finally, the area of newly formed bone 
was calculated using Image-pro Plus software. Four sections 
were examined microscopically for statistical analysis. 
 
2.9 Statistical analysis 
All data are expressed as Mean ± SD. Nonparametric test 
(Mann–Whitney U test), one-way analysis of variance (ANOVA) 
and the least significant difference (LSD) test were utilized to 
determine the level of significance; p < 0.05 was defined as 
statistically significant, and p < 0.01 was considered highly 
statistically significant. All statistical analyses of the data were 
performed using SPSS software (v19.0, USA). 
 
3. Results and discussion 
3.1 Establishment of segmental radial bone defects and 
characterization of scaffolds used in vivo 
 
Fig. 1 (A) Scaffolds used in animal model and SEM images of the surface morphology of 
the scaffolds. (B) Scaffold with a diameter of 4 mm and length of 10 mm was implanted 
into the segmental rabbit radial bone defect. (C) Radiographs of radial segmental defects 
with different implants taken at weeks 0, 4 and 8. 
Despite rapid advances, osteogenesis and vascularization of 
large bone grafts remains a major challenge hampering the 
clinical translation of bone substitute or tissue engineering 
scaffolds.1, 7, 29 The transformation of animal bone materials 
with ideal three-dimensional interconnected porous structures 
has attracted significant attention in recent years.10-11 The 
ability of bone substitute materials to provide both accelerated 
osteogenesis and vascularization is regarded as the gold 
standard. In our previous work,14 we demonstrated excellent 
biocompatibility, osteogenesis and vascularization of a 
HA/Ca/Mg scaffold possessing nano-crystal surface 
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microstructure capable of the release of bioactive ions in vitro. 
These positive in vitro results laid a solid foundation for 
subsequent in vivo research. In this study, we established a 
segmental radial bone defect model in rabbits (Fig. 1B). The 
scaffolds used in animal model with a diameter of 4 mm and 
length of 10 mm are shown in Fig. 1A. The surface morphology 
of HA and HA/Ca/Mg scaffolds were characterized using SEM. 
The micrograph showed that the HA/Ca/Mg scaffold had a 
nano-crystal whisker microstructure, which was consistent with 
our previous observations.14 Moreover, we used a macroporous 
scaffold (TCP), which has been widely used in clinical practice,16-
17 as control for the in vivo bioactivity of the HA/Ca/Mg scaffold. 
 
Fig. 2 (A) Representative Micro-CT images of segmental radial defects reconstructed at 
weeks 4 and 8. (B) and (C) Bone volume and BMD within the defects of the radius 
evaluated at weeks 4 and 8. *p<0.05 compared with HA scaffolds. #p<0.05 compared 
with TCP scaffolds. 
3.2 X-ray and Micro-CT evaluation of newly formed bone 
A bioactive scaffold should have the ability to stimulate a 
biological response in order to achieve effective osteogenesis at 
the position of the bone defect. For successful osteogenesis, the 
scaffold should exhibit highly bioactive interaction with 
osteoblasts.30-32 The regenerative ability of the scaffold could be 
improved by optimizing the biomaterial composition and 
properties or by the incorporation of bioactive ions that play a 
pivotal role in tissue repair.33 In our previous study,14 we 
demonstrated that the presence of a nano-crystal surface 
microstructure on bioactive scaffolds could effectively enhance 
cell attachment, spreading, proliferation and formation of focal 
adhesions, thus improving cytocompatibility of the scaffold in 
vitro. Meanwhile, the bioactive Ca2+ and Mg2+ ions released 
from the HA/Ca/Mg scaffold exerted a positive influence on the 
osteogenic differentiation of pre-osteoblasts. In this study, the 
in vivo radial bone defect healing was analyzed by X-ray and 
Micro-CT to assess the osteogenic potential of the HA/Ca/Mg 
scaffold. The results of X-ray analysis shown in Fig. 1C suggests 
that the different scaffolds used had varied degrees of bone 
healing efficacy. The best cortical regeneration and continuous 
bone callus formation were found in the HA/Ca/Mg group at 
weeks 4 and 8. We observed newly formed bones around and 
inside the HA/Ca/Mg scaffolds, effectively repairing the radial 
bone defects. The healing effect of the TCP scaffold was better 
than that of HA scaffold alone at weeks 4 and 8, and the HA 
scaffold displayed the slowest healing rate. The results of Micro-
CT (Fig. 2A) again indicated that the bone formation in the HA 
group was relatively smooth at week 4. However, different 
portions of bone contact were observed around TCP and 
HA/Ca/Mg scaffolds. At week 8, the efficiency of new bone 
formation in defects of the HA/Ca/Mg group was remarkably 
higher than those of the other groups. The volume of new bones 
(BV/TV) and BMD within the bone defects at weeks 4 and 8 
were calculated and given in Fig. 2B-C. From, which It is clear 
that the HA/Ca/Mg scaffold contained the highest bone volume 
and BMD (P < 0.05). 
 
Fig. 3 (A) Representative Micro-CT based angiography of vessels formed within the radial 
segmental defect region at weeks 4 and 8. (B) and (C) Vessels volume and vessel numbers 
within the defects evaluated at weeks 4 and 8. *p<0.05 compared with HA scaffolds. 
#p<0.05 compared with TCP scaffolds. 
3.3 Micro-CT evaluation of vascularization  
Vascularization at early stage after implantation is known to 
provide necessary oxygen and nourishment for cell repair, 
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tissue ingrowth and bone reconstruction.19,34 Importantly, it has 
been demonstrated that vascularization could establish a 
complicate microvascular system providing blood throughout 
the entire scaffold, which supports osteogenesis in bone 
defects.35-36 Moreover, vascularization for tissue regeneration 
can precede osteogenesis by well-established mechanisms, and 
the enhanced neovascularization can accelerate new bone 
formation.37-38 In the present study, the formation of new blood 
vessels in the radial bone defect at weeks 4 and 8 was analyzed 
by the Microfil experiment. The 3D images of 
neovascularization within the bone defect regions are given in 
Fig. 3A. After 4 and 8 weeks of implantation, abundant vessels 
were vividly displayed inside the HA/Ca/Mg scaffold whereas 
fewer blood vessels were seen inside the HA and TCP scaffolds. 
Compared with the HA and TCP groups, the HA/Ca/Mg group 
presented more new vessels with respect to the total vessel 
volume growing into the defects at weeks 4 and 8 (p＜0.05, Fig. 
3B). Vessel number within the scaffolds at weeks 4 and 8 post-
implantation is given in Fig. 3C. The HA/Ca/Mg group showed 
more newly formed vessels with perfused microfil located 
within the scaffolds at weeks 4 and 8, with a significant 
difference between HA and TCP groups (p＜0.05). These results 
were consistent with in vitro study that the bioactive scaffold 
could promote the vascularization process.14 According to the 
in vivo test, we hypothesized that the excellent ability of 
osteogenesis was partly due to its outstanding vascularization 
ability. It has been reported that the vascularization process in 
vivo is influenced by many factors, such as porosity, local active 
ion release and secretion of growth factors.39-40 
 
Fig. 4 Representative decalcified histological images in HA, TCP and HA/Ca/Mg scaffolds, obtained from longitudinal sections with implants at the defects of the radius. (A-D) H&E, 
Safranin O-fast green, Giemsa and Sirius red staining (×5, ×100) at weeks 4 and 8 after implantation. M: materials, NB: newly formed bone, F: fibrous tissue. 
3.4 Decalcified histological evaluation 
Biomaterials with a homogeneous, interconnected porous 
structure are required for bone substitutes or tissue 
engineering.42-43 An ideal porosity is conducive to cell 
recruitment of bone repair, vascular access, oxygen and tissue 
fluid exchange, and provides a good physiologically active space 
for bone ingrowth.15 In our previous study we demonstrated 
that the HA/Ca/Mg scaffold possessed relatively appropriate 
pore size, porosity and high pore connectivity.14 Histological 
observations were performed to analyse in more detail the 
regeneration process for the different scaffolds. The H&E and 
Giemsa staining results of the radial bone defects implanted 
with scaffolds for 4 and 8 weeks are shown in Fig. 4A and 4C. 
After implantation for 4 weeks, we observed that the HA 
scaffold pores were filled with loose fibrous connective tissue, 
and osteogenesis was barely detected. While in the TCP and 
HA/Ca/Mg groups, some newly formed bony bridging was seen 
in the defect region, which grew gradually into the central zone 
and the macropores of the scaffolds, closely combining with the 
trabecula of the scaffolds. We determined that more bone 
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matrix was deposited directly inside the pores in the HA/Ca/Mg 
scaffold than that in the TCP group, suggesting a good 
osseointegration inside the former scaffold. At week 8, the 
largest mature lamellar bone tissue was formed in the 
HA/Ca/Mg group, suggesting the best osteoconductivity and 
biocompatibility of the scaffold. Meanwhile, as shown in Fig. 4B 
and 4D, we also used Safranin O-fast green and Sirius red 
staining to reveal extensive collagenous matrix formation with 
the different scaffolds. After implantation for 4 and 8 weeks, we 
determined that bone defect healing was mostly marked by soft 
tissue callus formation in the HA scaffold. In the HA/Ca/Mg 
scaffold, we observed an intricate, dense and strong staining 
collagen matrix arrangement, which suggested that type I 
collagen, the main component of bone, was the largest 
component. Masson’s trichrome staining was used to assess the 
changes in bone morphology in Fig. 5A; the results indicated 
that the new bones originated from bone defect edges 
gradually formed along the external margins of the implant 
towards the centre of the scaffolds. The quantitative staining 
results of the new bone area are shown in Fig. 5B. Where it was 
revealed that, at week 4, the newly formed bone in TCP and 
HA/Ca/Mg groups were greater than that of the HA group (p < 
0.05), but there was no significant difference between the two 
groups (p > 0.05). However, at week 8, the HA/Ca/Mg group 
showed the largest new bone growth for all the scaffolds 
evaluated (p < 0.01). These results indicate that the bones could 
grow or migrate into the scaffolds through the macropores of 
the scaffolds, and denser bone regeneration was found in 
HA/Ca/Mg scaffold than the other scaffolds, which allowed a 
higher osteogenesis efficiency in vivo. Furthermore, the results 
of CD31 immunohistochemistry indicated a much better 
vascularization of the HA/Ca/Mg scaffold than other scaffolds 
(Fig. 5C), which was in agreement with the results obtained by 
Micro-CT. 
 
3.5 Undecalcified histological evaluation 
The osseointegration efficiency, which represents the direct 
contact between the newly formed bone and implant, also 
reflects the biocompatibility and other functions of the implant 
interface; therefore, an integrated bone-implant interface 
could facilitate long-term sustained osteogenesis.28,44-45 We 
used fluorescence labelling and undecalcified histological 
analysis to evaluate the osseointegration inside implants at the 
defects of the radius. The morphological changes in 
osteointegration between newly formed bone and implants 
trabecula on the transverse sections stained with Van Gieson 
are shown in Fig. 6A. 
 
Fig. 5 Representative decalcified histological images used to evaluate newly formed bone 
in HA, TCP and HA/Ca/Mg scaffolds, obtaining from longitudinal sections with implants 
at the defects of the radius. (A) Masson’s trichrome staining (×5, ×100) at weeks 4 and 8 
after implantation. (B) Quantitative analysis of the new bone area in stained sections at 
weeks 4 and 8 after implantation. (C) CD31 immunohistochemistry (×400) used to assess 
vascularization at weeks 4 and 8 after implantation. M: materials, NB: newly formed 
bone, F: fibrous tissue. *p＜0.05 compared with HA scaffolds. **p＜0.01 compared with 
HA scaffolds. ##p＜0.01 compared with TCP scaffolds. 
At week 4, minimal bone contact was observed around the HA 
scaffold, but obviously new bone tissues were in close contact 
with the trabecula on the edge of the TCP and HA/Ca/Mg 
scaffolds. At week 8, the bone tissue grown inside the HA 
scaffolds was also limited, while the HA/Ca/Mg scaffolds were 
covered with abundant bone tissues, especially in the central 
region of the scaffold. The quantitative results of newly formed 
bone in the osteointegration process are shown in Fig. 6B. At 
weeks 4 and 8, the HA/Ca/Mg group indicated the most 
compelling bone growth inside implants at the defects of the 
radius and displayed the best osteogenesis among all groups (p 
< 0.05 at week 4, p < 0.01 at week 8). Moreover, the newly 
formed bone inside the implants was fluorescently labelled and 
observed by CLSM; the results are given in Fig. 6C. A green-
yellow fluorescence was observed due to calcein labelling, while 
a red fluorescence was observed according to alizarin red 
labelling. The fluorescence could be used to exquisitely 
investigate the osteogenic process. The images implied that 
HA/Ca/Mg scaffold formed the largest region of mature 
mineralized bone tissue at week 8. The quantitative results of 
the fluorescence labelling were consistent with those of Van 
Gieson staining, which suggested that the HA/Ca/Mg scaffold 
had the best osteogenic capacity at both weeks 4 and 8 (Fig. 6D, 
p < 0.05 at weeks 4, p < 0.01 at weeks 8). Given that is well-
known, that the surface characteristics of biomaterials, such as 
composition, topography, and ion release, are very important 
for osseointegration.46-47 We believe that the improved 
osteointegration around the HA/Ca/Mg scaffold might be due 
to the synergistic effect of a combination of factors. 
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Fig. 6 Representative undecalcified histological images used to evaluate newly 
mineralized bone and osteointegration process in HA, TCP and HA/Ca/Mg scaffolds, 
obtainedg from transverse sections with implants at the defects of the radius. (A) Van 
Gieson staining (×5, ×100) at weeks 4 and 8 after implantation. (B) Quantitative analysis 
of the new bone area in Van Gieson staining. (C) Fluorescent micrographs labelled by 
calcein and alizarin red at weeks 4 and 8 after implantation. Green, calcein. Red, alizarin 
red. (D) Quantitative analysis of the new bone area in fluorescent labelling. *p＜0.05 
compared with HA scaffolds. **p＜ 0.01 compared with HA scaffolds. ##p＜ 0.01 
compared with TCP scaffolds. 
4. Conclusion 
With this research we have demonstrated the excellent capacity 
of our previously developed bioactive macroporous scaffold 
with interconnected porous structure and nano-crystal surface 
microstructure capable of bioactive ion release for bone 
regeneration. A variety of techniques were used to 
systematically investigate the bond-regeneration efficacy in 
vivo. Due to synergistic effects on the bone healing process, the 
bioactive scaffold exhibited outstanding osteogenesis, 
vascularization and osseointegration, as evidenced in a rabbit 
radial segmental bone defect model. In summary, the scaffold 
developed during this research might provide be a good clinical 
candidate as a bone substitute or tissue engineering scaffold. 
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